AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05462652 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Intervention
Description: The active intervention is a 5-week program divided into 5 levels intended to be completed weekly. Each level is expected to take about 60 minutes to complete. Activities in each level may include reading text on the screen, answering multiple choice style questions, swiping or clicking a button to move through screens, dragging and dropping elements on screen, and completing tasks outside of the app. Certain on-demand resources can be accessed in the apps at any time, including crisis resources. Where appropriate, text entries in the app that match a database of concerning words/phrases will trigger an automated pop-up suggesting participants visit the in-app crisis resources if they need additional support. Text entries will also be monitored by study staff for safety, though not in real-time. Participants will be instructed to complete a weekly PHQ-8 assessment in the mobile app.
Study NCT06364319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-CD25 rhMAb
Description: 1 mg/kg/day administered IV day 1, 4, and 8, then weekly for 6 doses. For patients achieving partial remission, an extra dose of Anti-CD25 rhMAb can be given on days 39 and 49.
Study NCT06364319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Maintain pre-screening dose
Study NCT06364319 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone
Description: Maintain pre-screening dose
Study NCT06364319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: 10mg, BID PO
Study NCT06364319 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ruxolitinib
Description: 10mg, BID PO
Study NCT06364319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: 1.25mg/kg, BID PO/IV, target:150-250ng/ml
Study NCT06364319 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cyclosporine
Description: 1.25mg/kg, BID PO/IV, target:150-250ng/ml
Study NCT06361992 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blue Cap Foam
Description: Application regimen: Blue Cap foam 100 ml, Activated Piroctone Olamine (Foam, label 100 ml), Catalysis S.L. Madrid must be applied twice a day on all affected areas. The application is to be continued for 30 days, after which the patients stop using the foam until the final assessment at day 45.
Study NCT05593601 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neomycin
Description: Neomycin (350 mg/tablet) 1.4 g three times a day (4.2 g per day) for 5 days
Study NCT06041776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Befotertinib + Icotinib placebo
Description: The initial dose of Befotertinib is 75 mg orally once daily (QD) for 21 days, and then increased to 100 mg orally QD in the absence of serious side effects , CTCAE grade ≥ 2 headache or thrombocytopenia during the 21 days.~Befotertinib can be taken on an empty stomach or after meals, and the medication is used until the disease relapses or intolerable toxicity occurs, or the treatment lasts for 3 years (disease recurrence includes local recurrence and/or distant metastasis)~Icotinib placebo 125 mg three times daily, on an empty stomach or in combination with food, use medication until the disease relapses or intolerable toxicity occurs or treatment lasts for 2 years (disease recurrence includes local recurrence and/or distant metastasis).
Study NCT05508594 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intranasal
Study NCT05508594 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sufentanil
Description: Intranasal
Study NCT06041776 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Icotinib + Befotertinib placebo
Description: Icotinib 125 mg three times daily, on an empty stomach or in combination with food, use medication until the disease relapses or intolerable toxicity occurs or treatment lasts for 2 years (disease recurrence includes local recurrence and/or distant metastasis).~The initial dose of Befotertinib placebo is 75 mg orally once daily (QD) for 21 days, and then increased to 100 mg orally QD in the absence of serious side effects , CTCAE grade ≥ 2 headache or thrombocytopenia during the 21 days.~Befotertinib placebo can be taken on an empty stomach or after meals, and the medication is used until the disease relapses or intolerable toxicity occurs, or the treatment lasts for 3 years (disease recurrence includes local recurrence and/or distant metastasis.
Study NCT04729946 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pure-Vu Cleansing Device
Description: The Pure-Vu device attaches to the colonoscope and provides colonic cleansing during urgent colonoscopy without the need for a bowel preparation
Study NCT05080244 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: 2 strains 10x10\^9 UFC/capsule
Study NCT05080244 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Potato starch and magnesium stearate
Study NCT05508594 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Intranasal
Study NCT06010875 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD70 CAR-T cells
Description: After lymphodepletion with Fludarabine and Cyclophosphamide,CAR T cells were transfused intravenically
Study NCT06010875 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD70 CAR-T cells
Description: After lymphodepletion with Fludarabine and Cyclophosphamide,CAR T cells were injected intraperitoneally
Study NCT05029570 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conduction System Pacing (pacemaker implantation)
Description: Conduction System Pacing (pacemaker implantation) and Atrioventricular node ablation
Study NCT05094440 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dialectical behavioral therapy skills training (DBT-ST)
Description: Pocket Skills is a dialectical behavior therapy skills training (DBT-ST) webapp that includes video lessons, an interactive chatbot AI coach, and in-app exercises to practice DBT skills. The delivery of the app will occur primarily over 1 month, followed by 2 months of follow-up, and will be supplemented with a walk through manual and links to DBT worksheets.
Study NCT05094440 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dialectical behavioral therapy skills training (DBT-ST)
Description: Pocket Skills is a dialectical behavior therapy skills training (DBT-ST) webapp that includes video lessons, an interactive chatbot AI coach, and in-app exercises to practice DBT skills. The delivery of the app will occur primarily over 1 month, followed by 2 months of follow-up, and will be supplemented with a walk through manual and links to DBT worksheets.
Study NCT05429515 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HFR-SUPRA
Description: HFR-SUPRA everyday for 3 days, then 3 times/week until patients do not require dialysis.
Study NCT05429515 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: hemodialysis
Description: hemodialysis everyday for 3 days, then 3 times/week until patients do not require dialysis.
Study NCT05429515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: chemotherapy protocol will be made by hematologists.
Study NCT05429515 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: chemotherapy protocol will be made by hematologists.
Study NCT04951739 — intervention group
Intervention type: PROCEDURE
Intervention: Peroral endoscopic myotomy
Description: Peroral endoscopic myotomy involves an initial incision on the internal lining of the oesophagus. This permits entry of the endoscope to within the wall of the oesophagus, where the muscle will be exposed. The inner layer of the muscle near the lower oesophagal sphincter will be cut (this is termed myotomy). At the conclusion of the procedure, the oesophagal incision will be closed with standard endoscopic clips.
Study NCT05125185 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The Effectiveness of USM-Insulin Adherence Module (U-IAM) for Type 2 Diabetes in Improving Insulin Adherence, Glycemic Control and Inflammation
Description: To study the effect of counseling using USM-Insulin Adherence Module (U-IAM) for Type 2 Diabetes in improving Insulin Adherence, Glycemic Control and Inflammation
Study NCT05125185 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Effectiveness of USM-Insulin Adherence Module (U-IAM) for Type 2 Diabetes in Improving Insulin Adherence, Glycemic Control and Inflammation
Description: To study the effect of counseling using USM-Insulin Adherence Module (U-IAM) for Type 2 Diabetes in improving Insulin Adherence, Glycemic Control and Inflammation
Study NCT06581627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etavopivat
Description: 2 tablets of Etavopivat will be administered in fasted state via oral route
Study NCT06510478 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Life Skill Intervention
Description: This 13-session life skills program covers essential topics in one-hour sessions. It starts with introductions and team building, then progresses through leadership, self-esteem, communication, stress management, positive thinking, confidence building, volunteering, decision-making, problem-solving, conflict resolution, and negotiation. Each session includes ice-breakers, discussions, and targeted exercises. Each session incorporates ice-breakers, open discussions, and targeted exercises to ensure active learning and skill internalization. Duration of each session was 1 hour.
Study NCT04806945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX10
Description: IV infusion.
Study NCT04806945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: IV infusion
Study NCT04806945 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: IV infusion
Study NCT04806945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: IV infusion
Study NCT04806945 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: IV infusion
Study NCT04806945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV infusion
Study NCT04806945 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin
Description: IV infusion
Study NCT04806945 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to HLX10
Description: IV infusion
Study NCT04564885 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BAGUERA®C Cervical Disc Prosthesis
Description: surgery
Study NCT04564885 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mobi-C Cervical Disc
Description: surgery
Study NCT03932097 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: REAL Parenting
Description: REAL Parenting digital intervention emphasizing parent-teen/young adult communication on drinking/risks of drinking/risks of alcohol abuse, with the addition of a communication component on the risks of nicotine and marijuana use, with the goal of reducing alcohol, nicotine and marijuana use in college students.
Study NCT03932097 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Control Materials
Description: NIAAA materials on underage drinking for parents
Study NCT06154681 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: World Digital Detox Family Program
Description: The Self-Help World Digital Detox Family Program spans four weeks and offers a structured approach to tackle the rising issues associated with the overuse of screens, social media, and digital devices within families. This intervention provides practical tools and strategies to be implemented on a weekly basis.
Study NCT06299423 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Howdy Senior® device
Description: Standard perioperative management plus three preoperative and twelve postoperative (until 90 days after surgery) HOWDY Senior® device assessments.
Study NCT05517460 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Auricular acupressure
Description: The participant in Intervention period will receive acupressure on ear Shenmen point, ear Large intestine point, ear Rectumn point and ear San Jiao point.
Study NCT05517460 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: health education
Description: health education for self-care and medication adherence
Study NCT06242444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental Dentifrice
Description: Dentifrice containing 1150 ppm fluoride and 5% KNO3.
Study NCT06242444 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Control Dentifrice
Description: Dentifrice containing 0 ppm fluoride and 5% KNO3.
Study NCT06242444 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reference Dentifrice
Description: Dentifrice containing 1100 ppm fluoride as SnF2.
Study NCT04681677 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation: Intra-operative Radiation Therapy - IORT
Description: Single fraction, Intra-operative Radiation Therapy at the time of surgical resection of recurrent GBM followed by Bevacizumab 28-56 days after surgery.
Study NCT04681677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab
Study NCT06048796 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early cessation of sedation and TTM
Description: Early cessation of sedation and TTM, with subsequent weaning from mechanical ventilation if appropriate
Study NCT06663293 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Conventional Nasal Cannula
Description: The initial flow rate for nasal cannula oxygen was set at 3 L/min. In cases of hypoxia, the oxygen concentration was adjusted by increasing the flow rate by 1 to 2 L/min.
Study NCT06510478 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group Life Skill Intervention
Description: This 13-session life skills program covers essential topics in one-hour sessions. It starts with introductions and team building, then progresses through leadership, self-esteem, communication, stress management, positive thinking, confidence building, volunteering, decision-making, problem-solving, conflict resolution, and negotiation. Each session includes ice-breakers, discussions, and targeted exercises. Each session incorporates ice-breakers, open discussions, and targeted exercises to ensure active learning and skill internalization. Duration of each session was 1 hour.
Study NCT06663293 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High-flow nasal cannula
Description: The high-flow nasal oxygenation device was set to a temperature of 36°C and an FiO2 of 0.4. The initial oxygen flow rate for the high flow group was determined according to the age and weight of the patients, based on our pediatric intensive care team's guidelines and the reference from the Slain study. When SpO2 fell below 94%, it was considered hypoxia, and the flow rate was increased by 2 to 4 L/min.
Study NCT06663293 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: midazolam, ketamine, propofol
Description: Sedation was done with IV midazolam 0.025 to 0.1 mg/kg, IV ketamine 0.25 to 0.5 mg/kg, and IV propofol (1%) 0.25 to 0.5 mg/kg
Study NCT06510478 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Treatment as Usual for Control Group
Description: Standard psychological interventions i.e. Debreathing, Meditation, supportive counseling, or psychoeducation.
Study NCT06663293 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: midazolam, ketamine, propofol
Description: Sedation was done with IV midazolam 0.025 to 0.1 mg/kg, IV ketamine 0.25 to 0.5 mg/kg, and IV propofol (1%) 0.25 to 0.5 mg/kg
Study NCT05630989 — intervention group
Intervention type: OTHER
Intervention: combination therapy with no MEKi
Description: This cohort will receive combination therapy with no MEKi.
Study NCT05630989 — intervention group
Intervention type: DRUG
Intervention: combination therapy with MEKi-HCQ
Description: This cohort will receive combination therapy with MEKi-HCQ.
Study NCT05630989 — intervention group
Intervention type: DRUG
Intervention: combination therapy with MEKi-EGFRi
Description: This cohort will receive combination therapy with MEKi-EGFRi.
Study NCT05630989 — intervention group
Intervention type: DRUG
Intervention: combination therapy with MEKi.
Description: This cohort will receive combination therapy with MEKi.
Study NCT06663293 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propofol
Description: Sedation maintenance was done by propofol 0.5 to 1 mg/kg/h
Study NCT06663293 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Sedation maintenance was done by propofol 0.5 to 1 mg/kg/h
Study NCT04606550 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Microablative Fractional CO2 Laser Therapy
Description: Microablative Fractional CO2 Vaginal Laser Therapy
Study NCT04606550 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microablative Fractional CO2 Laser Therapy
Description: Microablative Fractional CO2 Vaginal Laser Therapy
Study NCT05785767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fianlimab
Description: Every three weeks (Q3W) as intravenous (IV) co-infusion
Study NCT05785767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cemiplimab
Description: Q3W as IV co-infusion
Study NCT05785767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Q3W as IV co-infusion
Study NCT06672575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivonescimab
Description: Participante will recived an infusion by vein
Study NCT05970796 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic floor muscle training
Description: The pelvic floor muscle training program will be provided via an intra-vaginal biofeedback device - Smart Kegel Trainer, which will be connected to the product application installed on the mobile phone or tablet so the participants can monitor their pelvic floor contractions in real time and directly in the application. Participants will be asked to complete three sets of 8 to 12 maximal pelvic floor muscle contractions and three to ten fast contractions per training session. The home program will be tailored to each participant and include pelvic floor safe exercises recommended by the Continence Foundation of Australia.
Study NCT04737057 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SDF
Description: Apply this topical medication through : 1)Dry with a gentle flow of compressed air to decayed tooth surfaces. 2) Bend micro sponge brush to remove excess liquid before application apply SDF directly to only the affected tooth surface. 3) Apply the SDF material 4)Dry with a gentle flow of compressed air for at least one minute. and Remove excess SDF with gauze
Study NCT05877339 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Survey
Description: Survey
Study NCT06230094 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: moderate intensity
Description: Arm Circles, Leg Swings, Lunges, brisk walk
Study NCT06230094 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high intensity
Description: Arm circles, Leg swings, Lunges, skipping rope
Study NCT05900648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Given by PO
Study NCT05900648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XmAb20717
Description: Given by (IV) vein
Study NCT05187065 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The mobile-based education and exercise program
Description: Starting from the preoperative period, mobile-based patient education, progressive relaxation exercise and knee exercise program will be applied to the patient as a whole. Mobile-based education will include pre-operative and discharge education. The patient will be given a progressive relaxation exercise with the support of the mobile application and the exercises included in the knee exercise program that should be done after the surgery will be shown. Progressive relaxation exercises will be applied twice a day in the afternoon and evening. Postoperative knee exercises will be performed 3 to 5 times a day, depending on the type of exercise. These exercises will be continued regularly for up to 4 weeks after discharge.
Study NCT06412861 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: 0.5 mg/kg ketamine + 1 mg/kg propofol, Ramsey Sedation Score > 4 will be targeted. For this, if necessary, additional iv 0.5 mg/kg propofol will be administered.
Study NCT06412861 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: 1 mcg/kg fentanyl + 1 mg/kg propofol will be administered. Ramsay Sedation Score will be targeted to be > 4. For this, if necessary, additional iv 0.5 mg/kg propofol will be administered.
Study NCT04447313 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study NCT04447313 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Ancillary studies
Study NCT04447313 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone-Based Intervention
Description: Receive ACT telephone coaching
Study NCT04447313 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telephone-Based Intervention
Description: Receive SBT telephone coaching